Aleksandra Kawczyk-Krupka
Email:
ID:
David Aebisher
Email:
ID:
Dorota Bartusik-Aebisher
Email:
ID:
Grzegorz Cieślar
Email:
ID:
Magdalena Czarnecka-Czapczyńska
Email:
ID:

Abstract

Introduction. Coronavirus disease 2019 (COVID-19) was first observed in China in Wuhan city, Hubei province in December, 2019, and specified as a pandemic by the World Health Organization (WHO). COVID-19 is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2).

Aim. The aim of this article is to discuss epidemiology of thromboembolic complication in COVID-19.

Material and methods. This article is a review done in regards to discuss clinical features of the anticoagulation treatment in COVID-19.

Analysis of the literature. A review is discussed an anticoagulation treatment in 41 manuscripts.

Conclusion. Most commonly coagulation abnormalities in patient with COVID-19 is mild thrombocytopenia. Apart from their typical role in thrombosis and hemostasis, platelets mediate key aspects of immune and inflammatory.

Cite & Share

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. 

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited